Advanced search×

DNA vaccines against cancer come of age

Freda K Stevenson, Christian H Ottensmeier, and Jason Rice

Curr Opin Immunol 22(2):7 (2010) PMID 20172703

Genetic technology allows construction of DNA vaccines encoding selected tumor antigens together with molecules to direct and amplify the desired effector pathways. Their enormous promise has been marred by a problem of scaling up to human subjects. This is now largely overcome by electroporation, which increases both antigen expression and the inflammatory milieu. While the principles of vaccine design can be developed in mouse models, the real operative test is in the clinic, using patients in temporary remission. Monitoring of induced immunity, although commonly limited to blood, is providing objective qualitative and quantitative data on T-cell and antibody responses. Prolongation of remission is the goal and an activated immune system should achieve this.

Copyright © 2010 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.coi.2010.01.019
Version: za2963e q8zac q8zb3 q8zc2 q8zdc q8ze2 q8zf5 q8zg0

Similar articles you may find interesting…

  1. [The virtual infected cell: a systems biology rational for antiviral drug discovery].
    Vincent V Navratil, Vincent V Lotteau, and Chantal C Rabourdin-Combe

    Med Sci (Paris) 26(6-7):603-9 (2010) PMID 20619162

    We have reconstructed a prototype of the human virtual infected cell based on 30 years of intensive research in the field of molecular virology. This model contains more than one hundred viral infectomes, including major human pathogens (HCV, HBV, HIV, HHV, HPV) and has led to the generation of nove...
  2. [Respiratory papillomatosis--new methods of treatment].
    Katarzyna Nowaczewska, Piotr Wójtowicz, ... Marek Tulibacki

    Otolaryngol Pol 64(1):31-6 (2010) PMID 20476590

    We observed the patients during 28 months. 41 patients had 4 times intralesional injection of cidofovir. 18 patients had increased number of injection of ciodofovir because of recurrent papilloma. Rest of this group of the patients clinical studies showed remission disease. CONCLUSION: Surgery with...
  3. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
    M J SHALE, C H SEOW, ... S GHOSH

    Aliment Pharmacol Ther 31(1):20-34 (2010) PMID 19681818

    Particular risks are associated with the use of anti-TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti-viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti-TNF treatment, and may be particularly seve...